| 王 玲,刘伟仙,陈春妹,黄雄高,唐 平.康柏西普对糖尿病视网膜病变患者视网膜厚度及血清VEGF、IGF-1水平的影响[J].,2018,(18):3568-3571 |
| 康柏西普对糖尿病视网膜病变患者视网膜厚度及血清VEGF、IGF-1水平的影响 |
| Effects of Conbercept on Retinal Thickness and Serum VEGF and IGF-1 Levels in Patients with Diabetic Retinopathy |
| 投稿时间：2018-02-03 修订日期：2018-02-28 |
| DOI：10.13241/j.cnki.pmb.2018.18.038 |
| 中文关键词: 糖尿病视网膜病变 康柏西普 生活质量 疗效 血管内皮生长因子 胰岛素样生长因子-1 |
| 英文关键词: Diabetic retinopathy Conbercept Quality of life Clinical efficacy |
| 基金项目: |
|
| 摘要点击次数: 642 |
| 全文下载次数: 272 |
| 中文摘要: |
| 摘要 目的：探讨康柏西普对糖尿病视网膜病变患者视网膜厚度及血管内皮生长因子（VEGF）、胰岛素样生长因子-1（IGF-1）水平的影响。方法：以2015年1月~2017年1月在我院进行治疗的120例糖尿病视网膜病变患者进行研究，随机分为观察组和对照组，每组60例。对照组给予曲安奈德注射液治疗，观察组给予康柏西普眼用注射液治疗，两组均治疗1个月。观察并比较两组患者临床疗效、视网膜厚度、最佳矫正视力（BCVA）、VEGF、IGF-1、生活质量、不良反应等情况。结果：观察组患者总有效率为91.67%（55/60），高于对照组的76.67%（46/60）（P<0.05）。治疗后两组患者视网膜厚度、VEGF、IGF-1水平均低于治疗前，且观察组低于对照组，治疗后两组患者BCVA高于治疗前，且观察组高于对照组（P<0.05）。治疗后两组患者的生活质量评分均高于治疗前，且观察组高于对照组（P<0.05）。观察组不良反应发生率为6.67%（4/60），低于对照组的20.00%（12/60）（P<0.05）。结论：康柏西普治疗糖尿病视网膜病变患者的临床疗效显著，促进患者视力快速恢复，用药安全性好，能够提高患者生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of compacept on retinal thickness and the levels of serum VEGF and IGF-1 in pa- tients with diabetic retinopathy. Methods: 120 patients with diabetic retinopathy who were treated in our hospital from January 2015 to January 2017 were selected as research objects, and they were divided into observation group and control group according to random number table, 60 cases in each group. The control group was treated with Triamcinolone Acetonide injection, and the observation group was treated with compacept eye injection, and the two groups were treated for 1 months. The clinical efficacy, retinal thickness, best cor- rected visual acuity (BCVA), vascular endothelial growth factor(VEGF), insulin-like growth factor-1 (IGF-1), quality of life and adverse reactions were observed and compared between the two groups. Results: The total effective rate of the patients in the observation group was 91.67% (55/60), which was higher than that of the control group 76.67% (46/60)(P<0.05). After treatment, the retinal thickness, VEGF and IGF-1 levels of the two groups were all lower than those before treatment, and the observation group was lower than that of the control group. After treatment, the BCVA of the two groups was higher than that before treatment, and the observation group was higher than that of the control group (P<0.05). After treatment, the quality of life score of the two groups was higher than that before the treatment, and the observation group was higher than the control group, the difference was statistically significant(P<0.05). The inci- dence of adverse reactions in the observation group was 6.67% (4/60), which was lower than that of the control group (20% (12/60)(P<0.05). Conclusion: The clinical efficacy of conbercept in the treatment of diabetic retinopathy is significant. It can promote rapid recovery of vision, the safety of the drug is good, and it can improve the quality of life of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
